AnaptysBio (NASDAQ:ANAB) Releases Earnings Results, Misses Estimates By $0.82 EPS

AnaptysBio (NASDAQ:ANAB) announced its earnings results on Monday. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82), Yahoo Finance reports. The company had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. AnaptysBio had a negative return on equity of 161.40% and a negative net margin of 711.17%.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB traded down $0.54 during midday trading on Wednesday, hitting $31.54. 230,569 shares of the company’s stock were exchanged, compared to its average volume of 328,963. AnaptysBio has a 12 month low of $13.36 and a 12 month high of $38.85. The company has a market cap of $861.64 million, a PE ratio of -5.16 and a beta of -0.25. The stock has a 50 day moving average price of $28.03 and a 200-day moving average price of $25.11.

Insider Activity at AnaptysBio

In related news, CFO Dennis Mulroy sold 1,500 shares of AnaptysBio stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total transaction of $35,580.00. Following the transaction, the chief financial officer now owns 964 shares of the company’s stock, valued at $22,866.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Dennis M. Fenton sold 1,950 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $23.17, for a total value of $45,181.50. Following the transaction, the director now owns 1,950 shares in the company, valued at approximately $45,181.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Dennis Mulroy sold 1,500 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $23.72, for a total value of $35,580.00. Following the sale, the chief financial officer now directly owns 964 shares of the company’s stock, valued at $22,866.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,900 shares of company stock valued at $484,824. 33.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ANAB shares. Wells Fargo & Company assumed coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They set an “overweight” rating and a $56.00 target price for the company. JPMorgan Chase & Co. lifted their price objective on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday. Leerink Partnrs reaffirmed an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. SVB Leerink assumed coverage on AnaptysBio in a report on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of AnaptysBio in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $52.56.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.